Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ORINF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ORINF and 80,000+ other tickers.
See exactly how ORINF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ORINF and 80,000+ other tickers.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.
Orion Oyj (ORINF) Q2 2026 Earnings Call Transcript
Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript
Orion Oyj (ORINF) Q4 2025 Earnings Call Transcript
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 8 December 2025 below five (5) per cent of Orion Corporation's total shares.
Orion Oyj (OTCPK:ORINF) Q3 2025 Earnings Call October 28, 2025 7:30 AM EDT Company Participants Tuukka Hirvonen - Investor Relations & Financial Communications Officer Liisa Hurme - President, CEO & Chairman of Executive Management Board Rene Lindell - CFO & Member of Group Executive Management Board Conference Call Participants Sami Sarkamies - Danske Bank A/S, Research Division Shan Hama - Jefferies LLC, Research Division Anssi Raussi - SEB, Research Division Presentation Tuukka Hirvonen Investor Relations & Financial Communications Officer Okay. [Foreign Language] Good afternoon, and welcome to Orion's earnings conference call and webcast for the financial period of January-September 2025.